drugset / Trial / NCT06999187
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Non-randomizedSequentialOpen-labelTreatment
Summary
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Timeline
- Start
- 2025-06-03
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DR-0202 | Unknown | — | — |